September 14, 2018 BELOIT, Wis.--(BUSINESS WIRE)--The Board of Managers of NorthStar Medical Technologies, LLC (“NorthStar” or the “Company”), a global innovator in the production and distribution of radioisotopes used for medical imaging, today announced the appointment of Stephen Merrick as President and Chief Executive Officer. Mr. Merrick has been with NorthStar since March 2016, initially in the role of Chief Operating Officer and later as President and Chief Operating Officer.

Mr. Merrick replaces outgoing Chairman and Chief Executive Officer George Messina, who was named Chairman Emeritus. Mr. Messina was simultaneously appointed President and Chief Executive Officer of NorthStar Nuclear Therapies LLC (“NNT”), a wholly-owned subsidiary of NorthStar focused on developing medical isotopes for therapeutic applications. Diane Hendricks, Chairperson of Hendricks Holding Company, Inc. has assumed the Chairperson role for both Companies’ Board of Managers.

“As founder, George has been the driving force from NorthStar’s inception through FDA approval of the RadioGenix® System to the initial commercial sale of domestically produced Mo-99. We thank George for his successful leadership in NorthStar’s effort to become the first U.S.-based producer of Mo-99,” said Diane Hendricks, Chairperson of the NorthStar Board of Managers. “George’s passion and dedication were critical to building NorthStar into a global leader in the development of novel technologies for the production of medical isotopes for medical imaging. We are excited that George is assuming the leadership of NNT as President and Chief Executive Officer. Targeted Alpha Therapy (“TAT”) isotopes, including Actinium-225, produced by NNT have been identified as potential options in the treatment of certain cancers and infectious diseases. NNT’s therapeutic isotopes will offer more patients the potential for improved outcomes that were previously constrained by inadequate TAT isotope supply. We are looking to George to achieve similar success leading NNT as he has done with NorthStar.”
“NorthStar is at a transformative point in its evolution from a development stage company to being the first domestic supplier of Mo-99, and we are excited that Steve has agreed to become NorthStar’s President and CEO,” continued Ms. Hendricks. “This Company is strongly positioned for rapid growth in the U.S. market, and there are attractive opportunities for NorthStar to grow outside the United States as well. Steve’s broad executive experience in the pharmaceutical industry at Bristol-Myers Squibb, Mallinckrodt and Baxter Healthcare, as well as his expertise in product development and driving domestic and global market demand are invaluable to NorthStar’s future success. The Board of Managers believes that this organizational realignment allows NorthStar to capitalize on both George and Steve’s strengths.”

More People on the Move